Cargando…
Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation
The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising imm...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942037/ https://www.ncbi.nlm.nih.gov/pubmed/27404095 http://dx.doi.org/10.1371/journal.pone.0158907 |
_version_ | 1782442370513502208 |
---|---|
author | von Websky, Martin W. Kitamura, Koji Ludwig-Portugall, Isis Kurts, Christian von Laffert, Maximilian LeMaoult, Joel Carosella, Edgardo D. Abu-Elmagd, Kareem Kalff, Joerg C. Schäfer, Nico |
author_facet | von Websky, Martin W. Kitamura, Koji Ludwig-Portugall, Isis Kurts, Christian von Laffert, Maximilian LeMaoult, Joel Carosella, Edgardo D. Abu-Elmagd, Kareem Kalff, Joerg C. Schäfer, Nico |
author_sort | von Websky, Martin W. |
collection | PubMed |
description | The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising immunosuppressive effects of therapeutic HLA-G in experimental transplantation (skin allograft acceptance) were shown. Consequently, we examined this novel therapeutic approach in solid organ transplantation. In this study, therapeutic recombinant HLA-G5 was evaluated for the first time in a solid organ model of acute rejection (ACR) after orthotopic intestinal transplantation (ITX). Allogenic ITX was performed in rats (Brown Norway to Lewis) with and without HLA-G treatment. It was found that HLA-G treatment significantly reduced histologically proven ACR at both an early and late postoperative timepoint (POD 4/7), concomitant to a functionally preserved graft contractility at POD 7. Interestingly, graft infiltration by myeloperoxidase+ cells was significantly reduced at POD7 by HLA-G treatment. Moreover, HLA-G treatment showed an effect on the allogenic T-cell immune response as assessed by flow cytometry: The influx of recipient-derived CD8(+) T-cells into the graft mesenteric lymphnodes at POD7 was significantly reduced while CD4(+) populations were not affected. As a potential mechanism of action, an induction of T-reg populations in the mesenteric lymphnodes was postulated, but flow cytometric analysis of classical CD4(+)/CD25(+)/FoxP3(+)T(reg)-cells showed no significant alteration by HLA-G treatment. The novel therapeutic approach using recombinant HLA-G5 reported herein demonstrates a significant immunosuppressive effect in this model of allogenic experimental intestinal transplantation. This effect may be mediated via inhibition of recipient-derived CD8(+) T-cell populations either directly or by induction of non-classical T(reg) populations. |
format | Online Article Text |
id | pubmed-4942037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-49420372016-08-01 Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation von Websky, Martin W. Kitamura, Koji Ludwig-Portugall, Isis Kurts, Christian von Laffert, Maximilian LeMaoult, Joel Carosella, Edgardo D. Abu-Elmagd, Kareem Kalff, Joerg C. Schäfer, Nico PLoS One Research Article The non-classical MHC I paralogue HLA-G is expressed by cytotrophoblast cells and implicated with fetomaternal tolerance by downregulating the maternal adaptive and innate immune response against the fetus. HLA-G expression correlates with favorable graft outcome in humans and recently promising immunosuppressive effects of therapeutic HLA-G in experimental transplantation (skin allograft acceptance) were shown. Consequently, we examined this novel therapeutic approach in solid organ transplantation. In this study, therapeutic recombinant HLA-G5 was evaluated for the first time in a solid organ model of acute rejection (ACR) after orthotopic intestinal transplantation (ITX). Allogenic ITX was performed in rats (Brown Norway to Lewis) with and without HLA-G treatment. It was found that HLA-G treatment significantly reduced histologically proven ACR at both an early and late postoperative timepoint (POD 4/7), concomitant to a functionally preserved graft contractility at POD 7. Interestingly, graft infiltration by myeloperoxidase+ cells was significantly reduced at POD7 by HLA-G treatment. Moreover, HLA-G treatment showed an effect on the allogenic T-cell immune response as assessed by flow cytometry: The influx of recipient-derived CD8(+) T-cells into the graft mesenteric lymphnodes at POD7 was significantly reduced while CD4(+) populations were not affected. As a potential mechanism of action, an induction of T-reg populations in the mesenteric lymphnodes was postulated, but flow cytometric analysis of classical CD4(+)/CD25(+)/FoxP3(+)T(reg)-cells showed no significant alteration by HLA-G treatment. The novel therapeutic approach using recombinant HLA-G5 reported herein demonstrates a significant immunosuppressive effect in this model of allogenic experimental intestinal transplantation. This effect may be mediated via inhibition of recipient-derived CD8(+) T-cell populations either directly or by induction of non-classical T(reg) populations. Public Library of Science 2016-07-12 /pmc/articles/PMC4942037/ /pubmed/27404095 http://dx.doi.org/10.1371/journal.pone.0158907 Text en © 2016 von Websky et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article von Websky, Martin W. Kitamura, Koji Ludwig-Portugall, Isis Kurts, Christian von Laffert, Maximilian LeMaoult, Joel Carosella, Edgardo D. Abu-Elmagd, Kareem Kalff, Joerg C. Schäfer, Nico Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation |
title | Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation |
title_full | Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation |
title_fullStr | Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation |
title_full_unstemmed | Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation |
title_short | Recombinant HLA-G as Tolerogenic Immunomodulant in Experimental Small Bowel Transplantation |
title_sort | recombinant hla-g as tolerogenic immunomodulant in experimental small bowel transplantation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942037/ https://www.ncbi.nlm.nih.gov/pubmed/27404095 http://dx.doi.org/10.1371/journal.pone.0158907 |
work_keys_str_mv | AT vonwebskymartinw recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT kitamurakoji recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT ludwigportugallisis recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT kurtschristian recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT vonlaffertmaximilian recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT lemaoultjoel recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT carosellaedgardod recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT abuelmagdkareem recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT kalffjoergc recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation AT schafernico recombinanthlagastolerogenicimmunomodulantinexperimentalsmallboweltransplantation |